Sentence-ID,Sentence-String,Q1,Q2,Q3,Q4,Q5,Q6,Q7,Q8,Q9,Q10,Q11,Section
0,"Childhood apraxia of speech (CAS) affects a child's ability to produce sounds and syllables precisely and consistently, and to produce words and sentences with accuracy and correct speech rhythm.",0,0,0,0,0,0,0,0,0,0,0,Background
1,"It is a rare condition, affecting only 0.1% of the general population.",0,0,0,0,0,0,0,0,0,0,0,
2,Consensus has been reached that three core features have diagnostic validity: (1) inconsistent error production on both consonants and vowels across repeated productions of syllables or words; (2) lengthened and impaired coarticulatory transitions between sounds and syllables; and (3) inappropriate prosody (ASHA 2007).,0,0,0,0,0,0,0,0,0,0,1,
3,A deficit in motor programming or planning is thought to underlie the condition.,0,0,0,0,0,0,0,0,0,0,0,
4,This means that children know what they would like to say but there is a breakdown in the ability to programme or plan the fine and rapid movements required to accurately produce speech.,0,0,0,0,0,0,0,0,0,0,0,
5,"Children with CAS may also have impairments in one or more of the following areas: non‐speech oral motor function, dysarthria, language, phonological production impairment, phonemic awareness or metalinguistic skills and literacy, or combinations of these.",0,0,0,0,0,0,0,0,0,0,0,
6,High‐quality evidence from randomised controlled trials (RCTs) is lacking on interventions for CAS.,0,0,0,0,0,0,0,0,0,0,0,
7,To assess the efficacy of interventions targeting speech and language in children and adolescents with CAS as delivered by speech and language pathologists/therapists.,0,0,0,0,0,0,0,0,0,0,0,Objectives
8,"We searched CENTRAL, MEDLINE, Embase, eight other databases and seven trial registers up to April 2017.",0,0,0,0,0,0,0,0,0,0,0,Search methods
9,We searched the reference lists of included reports and requested information on unpublished trials from authors of published studies and other experts as well as information groups in the areas of speech and language therapy/pathology and linguistics.,0,0,0,0,0,0,0,0,0,0,0,
10,"RCTs and quasi‐RCTs of children aged 3 to 16 years with CAS diagnosed by a speech and language pathologist/therapist, grouped by treatment types.",0,0,0,0,0,0,0,0,0,0,0,Selection criteria
11,"Two review authors (FL, AM) independently assessed titles and abstracts identified from the searches and obtained full‐text reports of all potentially relevant articles and assessed these for eligibility.",1,0,0,0,0,0,0,0,0,0,0,Data collection and analysis
12,The same two authors extracted data and conducted the 'Risk of bias' and GRADE assessments.,0,0,0,0,0,0,0,0,0,0,0,
13,One review author (EM) tabulated findings from excluded observational studies (Table 1).,0,0,0,0,0,0,0,0,0,0,0,
14,"This review includes only one RCT, funded by the Australian Research Council; the University of Sydney International Development Fund; Douglas and Lola Douglas Scholarship on Child and Adolescent Health; Nadia Verrall Memorial Scholarship; and a James Kentley Memorial Fellowship.",0,0,0,0,0,0,0,0,0,0,0,Main results
15,"This study recruited 26 children aged 4 to 12 years, with mild to moderate CAS of unknown cause, and compared two interventions: the Nuffield Dyspraxia Programme‐3 (NDP‐3); and the Rapid Syllable Transitions Treatment (ReST).",0,0,0,0,0,0,0,0,0,0,0,
16,Children were allocated randomly to one of the two treatments.,0,1,0,0,0,0,0,0,0,0,0,
17,"Treatments were delivered intensively in one‐hour sessions, four days a week for three weeks, in a university clinic in Australia.",0,0,0,0,0,0,0,0,0,0,0,
18,Speech pathology students delivered the treatments in the English language.,0,0,0,0,0,0,0,0,0,0,0,
19,"Outcomes were assessed before therapy, immediately after therapy, at one month and four months post‐therapy.",0,0,0,0,0,0,0,0,0,0,0,
20,Our review looked at one‐month post‐therapy outcomes only.,0,0,0,0,0,0,0,0,0,0,0,
21,We judged all core outcome domains to be low risk of bias.,0,0,0,0,0,0,0,0,0,0,0,
22,"We downgraded the quality of the evidence by one level to moderate due to imprecision, given that only one RCT was identified.",0,0,0,0,0,0,0,0,0,0,0,
23,Both the NDP‐3 and ReST therapies demonstrated improvement at one month post‐treatment.,0,0,0,0,0,0,0,0,0,0,0,
24,A number of cases in each cohort had recommenced usual treatment by their speech and language pathologist between one month and four months post‐treatment (NDP‐3: 9/13 participants; ReST: 9/13 participants).,0,0,0,0,0,0,0,0,0,0,0,
25,"Hence, maintenance of treatment effects to four months post‐treatment could not be analysed without significant potential bias, and thus this time point was not included for further analysis in this review.",0,0,0,0,0,0,0,0,0,1,0,
26,"There is limited evidence that, when delivered intensively, both the NDP‐3 and ReST may effect improvement in word accuracy in 4‐ to 12‐year‐old children with CAS, measured by the accuracy of production on treated and non‐treated words, speech production consistency and the accuracy of connected speech.",0,0,0,0,0,0,0,0,0,0,0,
27,The study did not measure functional communication.,0,0,0,0,0,0,0,0,0,0,0,
28,"There is limited evidence that, when delivered intensively, both the NDP‐3 and ReST may effect improvement in word accuracy in 4‐ to 12‐year‐old children with CAS, measured by the accuracy of production on treated and non‐treated words, speech production consistency and the accuracy of connected speech.",0,0,0,0,0,0,0,0,0,0,0,Authors' conclusions
29,The study did not measure functional communication.,0,0,0,0,0,0,0,0,0,0,0,
30,"No formal analyses were conducted to compare NDP‐3 and ReST by the original study authors, hence one treatment cannot be reliably advocated over the other.",0,0,0,0,0,0,0,0,0,0,0,
31,We are also unable to say whether either treatment is better than no treatment or treatment as usual.,0,0,0,0,0,0,0,0,0,0,0,
32,No evidence currently exists to support the effectiveness of other treatments for children aged 4 to 12 years with idiopathic CAS without other comorbid neurodevelopmental disorders.,0,0,0,0,0,0,0,0,0,0,0,
33,Further RCTs replicating this study would strengthen the evidence base.,0,0,0,0,0,0,0,0,0,0,0,
34,"Similarly, further RCTs are needed of other interventions, in other age ranges and populations with CAS and with co‐occurring disorders.",0,0,0,1,0,0,0,0,0,0,0,
35,Plain language summary available in English  Español  Français  简体中文,0,0,0,0,0,0,0,0,0,0,0,
36,One well‐controlled study shows some evidence of effect of two interventions for childhood apraxia of speech (CAS),0,0,0,0,0,0,0,0,0,0,0,
37,What treatments help to improve the speech and language of children and adolescents with childhood apraxia of speech (CAS).,0,0,0,0,0,0,0,0,0,0,0,Review question
38,Children with CAS find it difficult to produce sounds and syllables consistently and precisely in order to speak words and sentences with clarity and correct speech rhythm.,0,0,0,0,0,0,0,0,0,0,0,Background
39,"As a result, children with CAS can be hard to understand with potential for negative impacts on school achievement and peer friendships.",0,0,0,0,0,0,0,0,0,0,0,
40,CAS affects around 0.1% of the general population.,0,0,0,0,0,0,0,0,0,0,0,
41,This review collates the research evidence to identify the most effective therapies for children with CAS.,0,0,0,0,0,0,0,0,0,0,0,
42,The evidence is current to 6 April 2017.,0,0,0,0,0,0,0,0,0,0,0,Search date
43,We found one study with 26 children aged 4 to 12 years with CAS.,0,0,0,0,0,0,0,0,0,0,0,Study characteristics
44,The children had mild to severe CAS without a known cause.,0,0,0,0,0,0,0,0,0,0,0,
45,Children were allocated randomly (using a method like coin tossing) to one of two treatments: the Nuffield Dyspraxia Programme ‐ Third Edition (NDP‐3); and the Rapid Syllable Transition treatment (ReST).,0,1,0,0,0,0,0,0,0,0,0,
46,"Both therapies were delivered intensively in one‐hour sessions, four days a week for three weeks.",0,0,0,0,0,0,0,0,0,0,0,
47,The treatments were delivered by speech pathology students in a university clinic.,0,0,0,0,0,0,0,0,0,0,0,
48,"Outcomes were assessed before therapy, immediately after therapy, at one month and four months post‐therapy.",0,0,0,0,0,0,0,0,0,0,0,
49,Our review looked at one‐month post‐therapy outcomes only.,0,0,0,0,0,0,0,0,0,0,0,
50,The included study was funded by the Australian Research Council; the University of Sydney International Development Fund; Douglas & Lola Douglas Scholarship on Child and Adolescent Health; Nadia Verrall Memorial Scholarship; and a James Kentley Memorial Fellowship.,0,0,0,0,0,0,0,0,0,0,0,Study funding sources
51,Further studies replicating these findings would strengthen available evidence.,0,0,0,0,0,0,0,0,0,0,0,Key results
52,The study provides limited evidence that the NDP‐3 may improve the accuracy of production on treated items and the accuracy of connected speech.,0,0,0,0,0,0,0,0,0,0,0,
53,"There is limited evidence that the NDP‐3 has a negligible effect on speech production consistency, and the ReST a negligible effect on accuracy of production on non‐treated words.",0,0,0,0,0,0,0,0,0,0,0,
54,The study did not measure functional communication.,0,0,0,0,0,0,0,0,0,0,0,
55,The included study was a randomised controlled trial with an overall low risk of bias.,0,0,0,0,0,0,0,0,0,0,0,Quality of the evidence
56,"We downgraded the quality of the evidence by one level to moderate, due to imprecision, given that only one RCT was identified.",0,0,0,0,0,0,0,0,0,0,0,
57,"There is limited evidence that the NDP‐3 or ReST may be helpful for children with CAS of unknown origin, aged 4 to 12 years, without other co‐occurring conditions.",0,0,0,0,0,0,0,0,0,0,0,Recommendations
58,"We were not able to find out whether one of these treatment was better than the other, or whether either was better than no treatment or treatment as usual.",0,0,0,0,0,0,0,0,0,0,0,
59,There is currently no available evidence for other treatments.,0,0,0,0,0,0,0,0,0,0,0,
60,Further RCTs — including studies comparing treatments to a no‐treatment (wait‐list) control group — would strengthen the evidence base.,0,0,0,0,0,0,0,0,0,0,0,
61,Further research is also needed for children with CAS and other disorders or diagnoses.,0,0,0,0,0,0,0,0,0,0,0,
62,"The present review concluded that there is only one RCT examining interventions for CAS in the literature to date, which requires replication.",0,0,0,0,0,0,0,0,0,0,0,Implications for practice
63,"This study provides some evidence that the NDP‐3 may improve the accuracy of production on treated items (words) and connected speech, but limited evidence that the NDP‐3 improves speech production consistency or that the ReST improves accuracy of production on non‐treated words.",0,0,0,0,0,0,0,0,0,0,0,
64,The study did not measure functional communication.,0,0,0,0,0,0,0,0,0,0,0,
65,"There are a range of further therapies reported in the literature ( Table 1), but the effectiveness of these interventions has not been rigorously examined; that is, other existing studies involve case study or case‐series investigations and not RCTs, limiting the ability to interpret and generalise findings to a broader population of children with CAS.",0,0,0,0,0,0,0,0,0,0,0,
66,"At present the evidence supports the use of NDP‐3 or ReST intervention programmes for children with idiopathic CAS, aged 4 to 12 years, without other co‐occurring neurodevelopmental deficits.",0,0,0,0,0,0,0,0,0,0,0,
67,Further well‐controlled studies investigating the effectiveness of other treatments for CAS are urgently needed.,0,0,0,0,0,0,0,0,0,0,0,
68,"There is a substantial range of treatments available for CAS; however, these require comparison with each other and to a no treatment (e.g.",0,0,0,0,0,0,0,0,0,0,0,
69,wait‐list control) group before their efficacy is rigorously demonstrated.,0,0,0,0,0,0,0,0,0,0,0,
70,Further trials are also needed that examine the efficacy of therapies for children with CAS with a range of co‐occurring neurodevelopmental impairments or diagnoses.,0,0,0,0,0,0,0,0,0,0,0,
71,There is a critical need for further rigorously controlled studies of treatment efficacy for CAS.,0,0,0,0,0,0,0,0,0,0,0,Implications for research
72,Replication of the work by Murray 2015 is required.,0,0,0,0,0,0,0,0,0,0,0,
73,Further work should also rigorously examine other CAS treatments reported in the literature.,0,0,0,0,0,0,0,0,0,0,0,
74,"RCTs and quasi‐RCTs are difficult to conduct given the heterogeneity of presentation of individuals with CAS, and due to the low incidence of the disorder.",0,0,0,0,0,0,0,0,0,0,0,
75,"However, the work of Murray 2015 shows RCTs are possible.",0,0,0,0,0,0,0,0,0,0,0,
76,"Future studies may also investigate further therapy implementation variables to increase our understanding of treatment response in this population, in particular considering dose, delivery, uptake and context, with examples given below.",0,0,0,0,0,0,0,0,0,0,0,
77,"Duration, dose, delivery, uptake and intensity of treatment (e.g.",0,0,0,0,0,0,0,0,0,0,0,
78,intervention once a week over 12 weeks or three sessions over five weeks),0,0,0,0,0,0,0,0,0,0,0,
79,Response of particular subgroups of participants to treatment (e.g.,0,0,0,0,0,0,0,0,0,0,0,
80,"subgroups based on age, genetic diagnosis, specific speech symptomatology), or dependent upon similarity of co‐occurring features (e.g.",0,0,0,1,0,0,0,0,0,0,0,
81,gross and fine motor or cognitive presentation),0,0,0,0,0,0,0,0,0,0,0,
82,Impact of timing of treatment (e.g.,0,0,0,0,0,0,0,0,0,0,0,
83,intervention at three years versus six years),0,0,0,0,0,0,0,0,0,0,0,
84,Effect of the administrator of treatment (e.g.,0,0,0,0,0,0,0,0,0,0,0,
85,"clinician, parent, teacher's aide or even participant‐administered therapy for older children)",0,0,0,0,0,0,0,0,0,0,0,
86,"Childhood apraxia of speech (CAS) affects a child's ability to produce speech sounds and syllables in the right order, and to speak words and sentences with accuracy and correct speech rhythm.",0,0,0,0,0,0,0,0,0,0,0,Description of the condition
87,"Over sixty years ago, Morley 1954 provided a seminal paper documenting a series of speech characteristics in children that resembled the speech production disorder of adults with acquired apraxia of speech, and the diagnosis of CAS was born.",0,0,0,0,0,0,0,0,0,0,0,
88,"CAS is a rare condition, affecting only around 0.1% of the general population (Morley 1972; Yoss 1975).",0,0,0,0,0,0,0,0,0,0,0,
89,"CAS is more prevalent within particular medical subgroups, however, and particularly penetrant in certain genetic syndromes (e.g.",0,0,0,0,0,0,0,0,0,0,0,
90,"Historically, synonyms such as verbal dyspraxia and developmental apraxia of speech have been used.",0,0,0,0,0,0,0,0,0,0,0,Fedorenko 2016; Mei 2017).
91,"The most commonly used terms today are CAS and developmental verbal dyspraxia (DVD), with the latter used largely in the UK context (RCSLT 2011).",0,0,0,0,0,0,0,0,0,0,0,
92,We use the term CAS consistently throughout this review.,0,0,0,0,0,0,0,0,0,0,0,
93,"A deficit in motor programming or planning is thought to underlie CAS; that is, children know what they would like to say but there is a breakdown in the ability to programme or plan the required movements to accurately produce speech.",0,0,0,0,0,0,0,0,0,0,0,
94,The current approach to diagnosis of CAS is expert‐based perception of speech symptoms (Maas 2012a).,0,0,0,0,0,0,0,0,0,0,0,
95,"There is consensus amongst speech and language pathologists (SLPs), also known as speech and language therapists (SLTs), that three core features of CAS have diagnostic validity: (1) inconsistent error production on both consonants and vowels across repeated productions of syllables or words; (2) lengthened and impaired coarticulatory transitions between sounds and syllables; and (3) inappropriate prosody (ASHA 2007).",0,0,0,0,0,0,0,0,0,0,1,
96,"In addition to the core features of CAS, children may also have co‐occurring impairments affecting non‐speech oral motor function, language, phonemic awareness/meta‐linguistics and literacy (ASHA 2007).",0,0,0,0,0,0,0,0,0,0,0,
97,"Younger children typically present with more severe forms of the disorder, with improvement noted over time for both idiopathic CAS (Davis 2005; Jacks 2006) and individuals with CAS associated with genetic syndromes (Morgan 2017; Morgan 2018).",0,0,0,0,0,0,0,0,0,0,0,
98,"It is not currently known how age, severity or underlying aetiology impact upon CAS treatment response or outcome.",0,0,0,1,0,0,0,0,0,0,0,
99,"There are no epidemiological data on the prevalence of CAS, although it occurs infrequently in comparison with other forms of developmental speech disorder such as articulation disorder and phonological disorder, which occur in around 3.5% of preschool children (Eadie 2015).",0,0,0,0,0,0,0,0,0,0,0,
100,"A population‐based estimate suggests that CAS occurs in one child per 1000 (0.1%) (Morley 1972; Yoss 1975), and is found in 3.4% to 4.3% of the children referred to clinics for speech disorder management (Delaney 2004).",0,0,0,0,0,0,0,0,0,0,0,
101,The diagnosis of CAS can apply to children who have a specific impairment in speech with other neurodevelopmental functions relatively more preserved (e.g.,0,0,0,0,0,0,0,0,0,0,0,
102,borderline or typical non‐verbal cognition).,0,0,0,0,0,0,0,0,0,0,0,
103,"Historically most cases were referred to as 'idiopathic', given limited aetiological knowledge of the condition (Morgan 2008).",0,0,0,0,0,0,0,0,0,0,0,
104,"In recent times, however, novel insights have been gained into the genetic and neurobiological bases of CAS (Eising 2018).",0,0,0,0,0,0,0,0,0,0,0,
105,"Variations in an increasing number of single genes have been associated with CAS (Eising 2018; Turner 2015), with the most replicated finding being disruption of the Forkhead box protein P2 or FOXP2 (Lai 2001; Morgan 2017; Vargha‐Khadem 2005).",0,0,0,0,0,0,0,0,0,0,0,
106,"Beyond single gene causes, CAS has also been associated with copy number variant syndromes, such as 16p11.2 deletion syndrome (Fedorenko 2016; Mei 2017), Koolen de Vries Syndrome (Morgan 2018), 6q25.3 deletion syndrome (Peter 2017), 7q11.23 duplication syndrome (Velleman 2011), and other genetic conditions such as Floating Harbour syndrome (White 2010).",0,0,0,0,0,0,0,0,0,0,0,
107,"Further to genetic causes, other medical conditions associated with CAS include metabolic disorders (e.g.",0,0,0,0,0,0,0,0,0,0,0,
108,galactosaemia; Shriberg 2011) or epilepsy disorders (e.g.,0,0,0,0,0,0,0,0,0,0,0,
109,"In relation to neurobiology or brain function, there is inconsistency as regards the key brain regions and networks disrupted in CAS, with neuroimaging studies reporting both cortical and subcortical anomalies (Liégeois 2012; Liégeois 2014; Liégeois 2016).",0,0,0,0,0,0,0,0,0,0,0,Liégeois 2012).
110,Description of the intervention,0,0,0,0,0,0,0,0,0,0,0,
111,A range of CAS treatment approaches with differing theoretical standpoints have been reported.,0,0,0,0,0,0,0,0,0,0,0,
112,These studies are almost exclusively in the form of uncontrolled case studies or case series.,0,0,0,0,0,0,0,0,0,0,0,
113,Therapeutic approaches for CAS can be grouped into the following three areas.,0,0,0,0,0,0,0,0,0,0,0,
114,"These therapies are based on principles of motor learning (see Maas 2008 for a review); for example, traditional articulation‐based drill therapy (Velleman 1994), the Nuffield Dyspraxia Programme (Williams 2004), the Rapid Syllable Transitions Treatment (Ballard 2010), rate control therapy (Rosenthal 1994), the PROMPT System (Prompts for Restructuring Oral MuscularPhonetic Targets) (Chumpelik 1984; Dale 2013), melodic intonation therapy (Helfrich‐Miller 1994), adapted cueing technique (Klick 1985), and integral stimulation or dynamic temporal and tactile cueing (Maas 2012a; Strand 2006).",0,0,0,0,0,0,0,0,0,0,0,Motor‐based approaches.
115,"Motor‐based therapy can also include non‐speech oro‐motor techniques; for example, oral form recognition training (Kingston 1987) and orofacial myofunctional therapy (Ray 2003).",0,0,0,0,0,0,0,0,0,0,0,
116,"Motor‐based therapy can also be instrumentally based, such as delayed auditory feedback (Lozano 1978), electropalatography (Carter 2004; Lundeborg 2007), and ultrasound (Preston 2013).",0,0,0,0,0,0,0,0,0,0,0,
117,Linguistic therapies address language impairments that can co‐occur in children with CAS.,0,0,0,0,0,0,0,0,0,0,0,Linguistic approaches.
118,Examples of linguistic approaches include programmes to address phonological speech production or awareness (McNeill 2009).,0,0,0,0,0,0,0,0,0,0,0,
119,Multi‐modal communication approaches.,0,0,0,0,0,0,0,0,0,0,0,
120,These approaches seek to support verbal communication.,0,0,0,0,0,0,0,0,0,0,0,
121,"Methods can address specific communication messages or features, such as Aided AAC (augmentative and alternative communication) Modelling (Binger 2007), or use of technological devices (Bornman 2001; Cumley 1999).",0,0,0,0,0,0,0,0,0,0,0,
122,How the intervention might work,0,0,0,0,0,0,0,0,0,0,0,
123,"Below, we describe the ways in which the aforementioned approaches (described under Description of the intervention) might work.",0,0,0,0,0,0,0,0,0,0,0,
124,"These methods use principles of motor learning, such as emphasizing a high number of successful repetitions of a task, using stimuli with high complexity, and a period of teaching followed by practice where cues and feedback are faded.",0,0,0,0,0,0,0,0,0,0,0,Motor‐based approaches.
125,Such approaches are reported to facilitate maintenance and generalisation in children with CAS (Maas 2008; Maas 2014).,0,0,0,0,0,0,0,0,0,0,0,
126,"These methods are focused on the semantics, phonology or grammar of language, and not on motor speech production per se.",0,0,0,0,0,0,0,0,0,0,1,Linguistic approaches.
127,"For example, a linguistic approach may include phonological contrast therapy, where children are taught how to abstract speech sound rules for the specific language(s) they speak (Dodd 2008).",0,0,0,0,0,0,0,0,0,0,0,
128,"Another example of a linguistic approach is core vocabulary therapy, which focuses on shaping children's word approximations whilst expanding their expressive and receptive vocabulary (Crosbie 2005).",0,0,0,0,0,0,0,0,0,0,0,
129,Multi‐modal communication approaches.,0,0,0,0,0,0,0,0,0,0,0,
130,These methods are used for children who are minimally verbal to help them communicate and reduce the frustration associated with their speech disability.,0,0,0,0,0,0,0,0,0,0,0,
131,"Devices may include a computer, phone or tablet with applications to help children produce words, phrases and sentences.",0,0,0,0,0,0,0,0,0,0,0,
132,"Other methods involve gesture, sign language or use of visual picture boards.",0,0,0,0,0,0,0,0,0,0,0,
133,Why it is important to do this review,0,0,0,0,0,0,0,0,0,0,0,
134,There is a need for clinicians and parents to be aware of the most efficacious treatments for children with CAS.,0,0,0,0,0,0,0,0,0,0,0,
135,"To date, studies in the field are largely non‐RCT (randomised controlled trials), single case series or case‐control studies that are generally positive in stating improvements in speech post‐therapy across motor (e.g.",0,0,0,0,0,0,0,0,0,0,0,
136,"Baas 2008; Ballard 2010; Edeal 2011; Hall 1989; Kadis 2014; McCabe 2014; Strand 2000; Strand 2006), linguistic (e.g.",0,0,0,0,0,0,0,0,0,0,0,
137,"McNeill 2009a; McNeill 2009b; McNeill 2010; Stokes 2010; Zaretsky 2010), and multi‐modal communication approaches (e.g.",0,0,0,0,0,0,0,0,0,0,0,
138,Harris 1996; King 2013; Tierney 2016).,0,0,0,0,0,0,0,0,0,0,0,
139,Yet these non‐RCT studies are inherently biased in nature and there is a need in the field for a systematic evaluation of available evidence.,0,0,0,0,0,0,0,0,0,0,0,
140,This review identifies best available treatments for CAS.,0,0,0,0,0,0,0,0,0,0,0,
141,This is an update of a Cochrane Review first published in 2008 (Morgan 2008).,0,0,0,0,0,0,0,0,0,0,0,
142,The previous review revealed no available RCTs for review.,0,0,0,0,0,0,0,0,0,0,0,
143,"The first RCT in this field was published in 2015, hence it was timely to provide an updated review.",0,0,0,0,0,0,0,0,0,0,0,
144,To assess the efficacy of interventions targeting speech and language in children and adolescents with CAS as delivered by speech and language pathologists/therapists.,0,0,0,0,0,0,0,0,0,0,0,Objectives
145,Criteria for considering studies for this review,1,0,0,0,0,0,0,0,0,0,0,Methods
146,studies in which participants are allocated to intervention groups on alternate days).,0,1,0,0,0,0,0,0,0,0,0,RCTs and quasi‐RCTs (e.g.
147,Children aged 3 to 16 years with a diagnosis of CAS made by a speech and language pathologist/therapist.,0,0,0,0,0,0,0,0,0,0,0,Types of participants
148,See Description of the intervention section above.,0,0,0,0,0,0,0,0,0,0,0,Types of interventions
149,Eligible control groups were no treatment control (e.g.,0,0,0,0,0,0,0,0,0,0,0,
150,"wait‐list control), treatment as usual, or other treatment controls.",0,0,0,0,0,0,0,0,0,0,0,
151,"Accuracy of production on treated or non‐treated* items (may be associated with motor‐based, linguistic or multi‐modal communication approaches noted under How the intervention might work)",0,0,0,0,0,0,0,0,0,0,0,Primary outcomes
152,"A desirable outcome would have been an improvement in accuracy of speech or multi‐modal communication, while an undesirable outcome would have been deterioration from baseline.",0,0,0,1,0,0,0,0,0,0,0,
153,*Non‐treated items are stimuli (e.g.,0,0,0,0,0,0,0,0,0,0,0,
154,"syllables, words, phrases) that have not been practised by children during intervention sessions.",0,0,0,0,0,0,0,0,0,0,0,
155,They are a form of control whereby we are able to measure children's performance on 'treated' items (e.g.,0,0,0,0,0,0,0,0,0,0,0,
156,"syllables, words, phrases the child has practised during speech sessions) and compare it with performance on 'non‐treated' items.",0,0,0,0,0,0,0,0,0,0,0,
157,"In this way, we can quantify whether the child has 'generalised' their newly acquired speech skills, or improvement in speech, to non‐treated stimuli, or whether they have only improved on speech items practised during therapy.",0,0,0,0,0,0,0,0,0,0,0,
158,"Speech production consistency across repeated words and syllables (may be associated with motor‐based, linguistic or multi‐modal communication approaches noted under How the intervention might work)",0,0,0,0,0,0,0,0,0,0,0,Secondary outcomes
159,"Accuracy of connected speech, including co‐articulation accuracy (e.g.",0,0,0,0,0,0,0,0,0,0,0,
160,"syllable segregation, voice onset time; most commonly associated with motor‐based or linguistic approaches noted under How the intervention might work)",0,0,0,0,0,0,0,0,0,0,0,
161,Functional communication (e.g.,0,0,0,0,0,0,0,0,0,0,0,
162,"child‐ or parent‐based questionnaire; may be associated with motor‐based, linguistic or multi‐modal communication approaches noted under How the intervention might work)",0,0,0,0,0,0,0,0,0,0,0,
163,"A desirable outcome would have been an improvement on outcomes one to three, whilst an undesirable outcome would have been deterioration from baseline on outcomes one to three.",0,0,0,1,0,0,0,0,0,0,0,
164,"Outcome measurements were recorded before, immediately after and at longer‐term follow‐up.",0,0,0,0,0,0,0,0,0,0,0,
165,Search methods for identification of studies,0,0,0,0,0,0,0,0,0,0,0,
166,"Margaret Anderson, Cochrane Information Specialist for the Developmental, Psychosocial and Learning Problems Group, conducted the searches for this update in August 2011, June 2014 and April 2017.",0,0,0,0,0,0,0,0,0,0,0,Electronic searches
167,"We searched the following list of sources which includes bibliographic databases, and international and national trials registers.",0,0,0,0,0,0,0,0,0,0,0,
168,"We did not apply any date restrictions, but we only examined articles written in the English language.",0,0,0,0,0,0,0,0,0,0,0,
169,We report the search strategies for this update in Appendix 1.,0,0,0,0,0,0,0,0,0,0,0,
170,Earlier search strategies are in Appendix 2.,0,0,0,0,0,0,0,0,0,0,0,
171,"Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 3) in the Cochrane Library, and which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialized Register (searched 6 April 2017)",0,0,0,0,0,0,0,0,0,0,0,
172,Ovid MEDLINE (1946 to March week 5 2017),0,0,0,0,0,0,0,0,0,0,0,
173,Ovid MEDLINE E‐Pub Ahead of Print (searched 6 April 2017),0,0,0,0,0,0,0,0,0,0,0,
174,Ovid MEDLINE In Process & Other Non‐indexed Citations (searched 6 April 2017),0,0,0,0,0,0,0,0,0,0,0,
175,Embase Ovid (1980 to 2017 week 15),0,0,0,0,0,0,0,0,0,0,0,
176,CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature; 1937 to 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
177,PsycINFO Ovid (1806 to April week 1 2017),0,0,0,0,0,0,0,0,0,0,0,
178,PsycINFO EBSCOhost (1887 to 4 August 2011),0,0,0,0,0,0,0,0,0,0,0,
179,ERIC EBSCOhost (Education Resources Information Center; 1966 to 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
180,ERIC Proquest (Education Resources Information Center; 1966 to 6 June 2014),0,0,0,0,0,0,0,0,0,0,0,
181,"Cochrane Database of Systematic Reviews (CDSR; 2017, Issue 4) part of the Cochrane Library",0,0,0,0,0,0,0,0,0,0,0,
182,"Database of Abstracts of Reviews of Effect (DARE; 2015, Issue 2) part of the Cochrane Library (not searched in previous version of review (Morgan 2008).",0,0,0,0,0,0,0,0,0,0,0,
183,Final issue published in 2015),0,0,0,0,0,0,0,0,0,0,0,
184,SpeechBITE (speechbite.com; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
185,Australian New Zealand Clinical Trials Registry (ANZCTR; www.anzctr.org.au/BasicSearch.aspx; searched 12 April 2017),0,0,0,0,0,0,0,0,0,0,0,
186,Chinese Clinical Trial Registry (ChiCTR; www.chictr.org.cn; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
187,ClinicalTrials.gov (clinicaltrials.gov; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
188,EU Clinical Trials Register (clinicaltrialsregister.eu; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
189,ISRCTN Registry (www.isrctn.com; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
190,Nederlands Trial Register (trialregister.nl/trialreg/admin; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
191,World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; www.who.int/ictrp/en; searched 10 April 2017),0,0,0,0,0,0,0,0,0,0,0,
192,"We searched the reference lists of included reports, and requested information on unpublished trials from authors of published studies and other experts, as well as information groups in the areas of speech and language therapy/pathology and linguistics.",0,0,0,0,0,0,0,0,0,0,0,Searching other resources
193,"We were unable to use many of our preplanned methods (Morgan 2006), as only one study met the inclusion criteria (Criteria for considering studies for this review).",1,0,0,0,0,0,0,0,0,0,0,Data collection and analysis
194,"This study was published in a peer‐reviewed journal and there are no other completed RCTs or quasi‐RCTs at this time, published or unpublished.",0,0,0,0,0,0,0,0,0,0,0,
195,See Appendix 3 and Morgan 2006.,0,0,0,0,0,0,0,0,0,0,0,
196,Two review authors (FL and AM) independently screened all titles and abstracts yielded by the search for eligibility.,1,0,0,0,0,0,0,0,0,0,0,Selection of studies
197,"In cases of uncertainty over whether an abstract met the inclusion criteria, we obtained the full‐text report.",1,0,0,0,0,0,0,0,0,0,0,
198,"Next, the same two reviewers independently evaluated each full‐text report against the inclusion criteria (Criteria for considering studies for this review).",1,0,0,0,0,0,0,0,0,0,0,
199,"In the event of disagreement over inclusion of a particular paper, FL and AM reached consensus by re‐assessing the study against the inclusion criteria together.",1,0,0,0,0,0,0,0,0,0,0,
200,We present the results of our selection process in a PRISMA diagram; see Figure 1 (Moher 2009).,0,0,0,0,0,0,0,0,0,0,0,
201,Data extraction and management,0,0,0,0,0,0,0,0,0,0,0,
202,"In addition to outcome data, we documented the following information using a data management form: participant details; setting (e.g.",0,0,0,0,0,0,0,0,0,0,0,
203,"community clinic, school); type of intervention; length and frequency of intervention; professions involved; duration of impairment; level of severity; co‐morbidity; and assessment tools employed.",0,0,0,0,0,0,0,0,0,0,0,
204,We requested any information that was missing or unclear from the corresponding author (Dealing with missing data).,0,0,0,0,0,0,0,0,0,0,0,
205,"AM independently extracted and entered the outcome data into Review Manager 5 (Review Manager 2014), and FL then independently evaluated the data and entries.",0,0,0,0,0,0,0,0,0,0,0,
206,AM and FL discussed any disagreements until they reached a consensus.,0,0,0,0,0,0,0,0,0,0,0,
207,EM entered further details of excluded studies into Table 1.,0,0,0,0,0,0,0,0,0,0,0,
208,"Excluded, low‐quality evidence from observational studies (case‐series, case control)",0,0,0,0,0,0,0,0,0,0,0,Table 1.
209,Assessment of risk of bias in included studies,0,0,0,0,0,0,0,0,0,0,0,
210,"Two review authors (FL and AM) independently assessed the risk of bias within the one included study, using Cochrane's 'Risk of bias' tool (Higgins 2011a).",0,0,0,0,0,0,0,0,0,0,0,
211,"Both review authors rated the risk of bias as low, high or unclear (uncertain), across each of the domains listed below.",0,0,0,0,0,0,0,0,0,0,0,
212,There were no cases of disagreement.,0,0,0,0,0,0,0,0,0,0,0,
213,Did the study describe the method used to generate the allocation sequence in sufficient detail to determine whether it produced comparable groups?,0,0,1,0,0,0,0,0,0,0,0,Sequence generation.
214,"In the review authors' judgment, was the sequence adequately generated?",0,0,0,0,0,0,0,0,0,0,0,
215,"Did the study describe the method used to conceal the allocation sequence in sufficient detail to assess whether intervention schedules could have been foreseen in advance of, or during, recruitment?",0,0,1,0,0,0,0,0,0,0,0,Allocation concealment.
216,"In the review authors' judgment, was allocation adequately concealed?",0,0,1,0,0,0,0,0,0,0,0,
217,Blinding of participants and personnel.,0,0,0,0,1,1,1,0,0,0,0,
218,Did the study describe any measures used to blind participants and personnel from knowledge of which intervention a given participant might have received?,0,0,0,0,1,1,1,0,0,0,0,
219,"In the review authors' judgment, was knowledge of the allocated interventions adequately concealed from participants and relevant personnel during the study?",0,0,1,0,0,0,0,0,0,0,0,
220,Blinding of outcome assessment.,0,0,0,0,1,1,1,0,0,0,0,
221,Did the study describe any measures used to blind outcome assessors from knowledge of which intervention a given participant might have received?,0,0,0,0,1,1,1,0,0,0,0,
222,"In the review authors' judgment, was knowledge of the allocated interventions adequately concealed from all outcome assessors during the study?",0,0,1,0,0,0,0,0,0,0,0,
223,"Did the study report data on attrition and exclusions as well as the numbers involved (compared with total randomised), reasons for attrition/exclusion, and any re‐inclusions in analyses performed.",0,0,0,0,0,0,0,1,0,0,0,Incomplete outcome data.
224,"In the review authors' judgment, did the study authors deal adequately with incomplete data?",0,0,0,0,0,0,0,0,0,0,0,
225,Did the study make attempts to assess the possibility of selective outcome reporting?,0,0,0,0,0,0,0,0,0,0,0,Selective outcome reporting.
226,"In the review authors' judgment, are reports of the study free of suggestion of selective outcome reporting determined by comparing the outcomes listed in the original study protocol with the final RCT publication?",0,0,0,0,0,0,0,0,0,0,0,
227,Was the study apparently free of other problems that could put it at a high risk of bias?,0,0,0,0,0,0,0,0,0,0,0,Other sources of bias.
228,"In the review authors' judgement, was the study free of other problems not covered by the domains above?",0,0,0,0,0,0,0,0,0,0,0,
229,We were unable to conduct a meta‐analysis due to there being only one included study.,0,0,0,0,0,0,0,0,0,0,0,Measures of treatment effect
230,We have archived our methods for use in future updates of this review (see Appendix 3; Morgan 2006).,0,0,0,0,0,0,0,0,0,0,0,
231,"For each outcome measure, we averaged the accuracy of production (e.g.",0,0,0,0,0,0,0,0,0,0,0,Unit of analysis issues
232,number of correct items from total items elicited) across the group.,0,0,0,0,0,0,0,0,0,0,0,
233,Units were mean accuracy scores for each intervention group.,0,0,0,0,0,0,0,0,0,0,1,
234,See Appendix 3 for additional methods archived for use in future updates of this review.,0,0,0,0,0,0,0,0,0,0,0,
235,"There were missing data for 1/26 participants in the Murray 2015 RCT, due to a participant withdrawing in the middle of treatment (see Appendix 3 and Morgan 2006).",0,0,0,0,0,0,0,0,0,0,0,Dealing with missing data
236,We were unable to assess heterogeneity as only one study met the inclusion criteria (see Appendix 3 and Morgan 2006).,1,0,0,0,0,0,0,0,0,0,0,Assessment of heterogeneity
237,Assessment of reporting biases,0,0,0,0,0,0,0,0,0,0,0,
238,We were unable to assess reporting biases due to there being only one included study (see Appendix 3 and Morgan 2006).,0,0,0,0,0,0,0,0,0,0,0,
239,We could not undertake a meta‐analysis as we included only one study in the review (see Appendix 3 and Morgan 2006).,0,0,0,0,0,0,0,0,0,0,0,Data synthesis
240,"Using GRADEpro GDT (GRADEpro GDT 2015), we created a 'Summary of findings' table for the comparison: Nuffield Dyspraxia Programme ‐ Third Edition (NDP‐3) versus Rapid Syllable Transition Treatment (ReST) for Childhood Apraxia of Speech.",0,0,0,0,0,0,0,0,0,0,0,Summary of findings
241,In this table we report our primary (accuracy of production on treated and non‐treated items) and secondary (speech production consistency and accuracy of connected speech) outcomes for one month post‐treatment.,0,0,0,0,0,0,0,0,0,0,0,
242,We chose this time point as it is the most clinically salient time point.,0,0,0,0,0,0,0,0,0,0,0,
243,The time point immediately after therapy is not sufficient to determine whether the treatment effect was sustained.,0,0,0,0,0,0,0,0,0,0,0,
244,"We did not examine the time point of four months post‐therapy because the number of participants in each group (NDP‐3: 9/13 participants; ReST: 9/13 participants) had returned to community SLP/SLT treatment between the one‐month and four‐month post‐therapy period and, as such, it would be difficult to delineate between a sustained treatment effect of the RCT versus the usual therapy re‐introduced.",0,0,0,0,0,0,0,0,0,0,0,
245,We also report in this table the quality ratings for each outcome as assessed by two review authors (AM and FL) using the GRADE approach (Schünemann 2017).,0,0,0,0,0,0,0,0,0,0,0,
246,"They assigned ratings of high, moderate, low or very low quality, according to the presence of risk of bias (Risk of bias in included studies), indirectness of evidence, unexplained heterogeneity or inconsistency in results, imprecision of results and high probability of publication bias; they discussed any disagreements over the quality ratings until a consensus was reached.",0,0,0,0,0,0,0,0,0,0,0,
247,Please see 'summary of findings Table for the main comparison' for an overview of treatment effects for each outcome measure and GRADE assessment of the quality of the evidence.,0,0,0,0,0,0,0,0,0,0,0,
248,Subgroup analysis and investigation of heterogeneity,0,0,0,0,0,0,0,0,0,1,0,
249,We were unable to perform any subgroup analyses as we included only one study in the review.,0,0,0,0,0,0,0,0,0,0,0,
250,See Appendix 3 and Morgan 2006.,0,0,0,0,0,0,0,0,0,0,0,
251,We were unable to perform a sensitivity analysis as we included only one study in the review.,0,0,0,0,0,0,0,0,0,1,0,Sensitivity analysis
252,See Appendix 3 and Morgan 2006.,0,0,0,0,0,0,0,0,0,0,0,
253,We identified a total of 7978 records once duplicates were discarded.,0,0,0,0,0,0,0,0,0,0,0,Results of the search
254,EM identified a further 16 records through handsearching.,0,0,0,0,0,0,0,0,0,0,0,
255,"Of these 7994 titles and abstracts, we excluded 7895 as clearly irrelevant, and assessed the full texts of the remaining 99 reports against our inclusion criteria (Criteria for considering studies for this review).",1,0,0,0,0,0,0,0,0,0,0,
256,"From these 99 reports, only one study met our inclusion criteria for this review (Included studies); we excluded the remaining 98 reports as irrelevant (see Excluded studies).",1,0,0,0,0,0,0,0,0,0,0,
257,We did not identify any non‐English abstracts for inclusion.,1,0,0,0,0,0,0,0,0,0,0,
258,"The one included study, Murray 2015, was an RCT that compared treatment effects for two interventions, each delivered intensively (one hour for four days a week for three weeks): the Nuffield Dyspraxia Programme ‐ Third Edition (NDP‐3; Williams 2004) and the Rapid Syllable Transition treatment (ReST; Ballard 2010).",0,0,0,0,0,0,0,0,0,0,0,Included studies
259,"Twenty‐six children (13 allocated to each therapy group), aged 4 to 12 years (18 males) with CAS diagnosed by a SLP/SLT participated in the study, which took place at the University of Sydney Communication Disorders Treatment and Research Clinic.",0,0,0,0,0,0,0,0,0,0,0,
260,The primary outcomes were per cent accuracy on treated and untreated pseudo‐words and real words and phrases.,0,0,0,0,0,0,0,0,0,0,0,
261,"The research was funded (as published in the article) by: Douglas and Lola Douglas Scholarship on Child and Adolescent Health; Nadia Verrall Memorial 2010; and Postgraduate Student Scholarship 2011 through Speech Pathology Australia, James Kentley Memorial Scholarship, Postgraduate Research Support Schemes and Faculty of Health Sciences; University of Sydney International Development Program Fund, and the Australian Research Council Future Fellowship.",0,0,0,0,0,0,0,0,0,0,0,
262,Please see the Characteristics of included studies table for further detail of the nature of these interventions.,0,0,0,0,0,0,0,0,0,0,0,
263,We excluded 98 full‐text reports.,0,0,0,0,0,0,0,0,0,0,0,Excluded studies
264,"Of these, 29 studies were either not interventions (e.g.",0,0,0,0,0,0,0,0,0,0,0,
265,"diagnostic studies), or did not include participants with CAS (e.g.",0,0,0,0,0,0,0,0,0,0,0,
266,focused on other speech disorders or adult‐acquired apraxia of speech).,0,0,0,0,0,0,0,0,0,0,0,
267,"The remaining 69 excluded papers were CAS intervention studies but were not RCTs, and are tabulated in Characteristics of excluded studies tables.",0,0,0,0,0,0,0,0,0,0,0,
268,Further detail on the excluded CAS studies is provided in Table 1.,0,0,0,0,0,0,0,0,0,0,0,
269,Risk of bias in included studies,0,0,0,0,0,0,0,0,0,0,0,
270,"We examined the one included study, Murray 2015, for risk of bias.",0,0,0,0,0,0,0,0,0,0,0,
271,"We judged the study to be at low risk of bias for all domains except 'other sources of bias', which we judged to be at unclear risk of bias.",0,0,0,0,0,0,0,0,0,0,0,
272,"Please see the 'Risk of bias' table (beneath the Characteristics of included studies table) for further detail on the basis of our decisions, and Figure 2 for a summary of ratings.",0,0,0,0,0,0,0,0,0,0,0,
273,Risk of bias summary: review authors' judgements about each risk of bias item for each included study.,0,0,0,0,0,0,0,0,0,0,0,
274,See: Summary of findings for the main comparison,0,0,0,0,0,0,0,0,0,0,0,Effects of interventions
275,"We downgraded the quality of the evidence by one level to moderate due to imprecision, given that only one RCT was identified.",0,0,0,0,0,0,0,0,0,0,0,
276,Primary outcome: accuracy of production,0,0,0,0,0,0,0,0,0,0,0,
277,The Murray 2015 study compared the number of real words produced correctly (out of the total elicited words) at pre‐treatment with one month post‐treatment for treated and non‐treated items.,0,0,0,0,0,0,0,0,0,0,0,
278,"The study authors reported that, compared to pre‐treatment baseline, the NDP‐3 MD of 36.0 was greater than the ReST MD of 33.9 at one month post‐treatment, with an absolute mean difference of 2.1 between groups.",0,0,0,1,0,0,0,0,0,0,1,Treated items
279,"The study authors reported that, compared to pre‐treatment baseline, the ReST MD of 18.3 was minimally greater than the NDP‐3 MD of 18.2 at one month post‐treatment with an absolute mean difference of 0.1 between groups.",0,0,0,1,0,0,0,0,0,0,1,Non‐treated items
280,"The Murray 2015 study compared treatment gains in speech production consistency (measured by 25 real words repeated three times using the inconsistency subtest of the Diagnostic Evaluation of Articulation and Phonology (DEAP) test (Dodd 2006)), at pre‐treatment with one month post‐treatment for treated items.",0,0,0,0,0,0,0,0,0,0,0,Speech production consistency
281,"The study authors reported that, compared to pre‐treatment baseline, the NDP‐3 MD of 11.1 was minimally greater than the ReST MD of 10.9 at one month post‐treatment, with an absolute mean difference of 0.2 between groups.",0,0,0,1,0,0,0,0,0,0,1,
282,"The Murray 2015 study compared treatment gains in the accuracy of connected speech (as assessed by imitated word accuracy in connected speech of at least three word combinations), at pre‐treatment with one month post‐treatment for treated items.",0,0,0,0,0,0,0,0,0,0,0,Accuracy of connected speech
283,"The study authors reported that, compared to pre‐treatment baseline, the NDP‐3 MD of 14.3 was greater than the ReST MD of 11.5 at one month post‐treatment, with an absolute mean difference of 2.8 between groups.",0,0,0,1,0,0,0,0,0,0,1,
284,The study did not measure functional communication.,0,0,0,0,0,0,0,0,0,0,0,
285,"We sought to investigate the effectiveness of targeted speech and language interventions for children and young people, aged 3 to 16 years of age, with a diagnosis of CAS made by a speech and language pathologist/therapist.",0,0,0,1,0,0,0,0,0,0,0,Summary of main results
286,"We found only one study, Murray 2015, which met our inclusion criteria (Criteria for considering studies for this review).",1,0,0,0,0,0,0,0,0,0,0,
287,"This RCT recruited 26 children aged 4 to 12 years, and compared two interventions: the Nuffield Dyspraxia Programme‐3 (NDP‐3); and the Rapid Syllable Transitions Treatment (ReST).",0,0,0,0,0,0,0,0,0,0,0,
288,"Treatments were delivered intensively in one‐hour sessions, four days a week for three weeks, in a university clinic in Australia.",0,0,0,0,0,0,0,0,0,0,0,
289,Speech pathology students delivered the treatments in the English language.,0,0,0,0,0,0,0,0,0,0,0,
290,We considered all core domains to be at low risk of bias.,0,0,0,0,0,0,0,0,0,0,0,
291,Both the NDP‐3 and ReST therapies demonstrated improvement at one month post‐treatment.,0,0,0,0,0,0,0,0,0,0,0,
292,A number of cases in each cohort had recommenced usual treatment by their speech and language pathologist between one month and four months post‐treatment (NDP‐3: 9/13 participants; ReST: 9/13 participants).,0,0,0,0,0,0,0,0,0,0,0,
293,"Hence we could not analyse maintenance of treatment effects to four months post‐treatment without significant potential bias, and so we did not include this time point for further analysis in this review.",0,0,0,0,0,0,0,0,0,1,0,
294,"Overall there is limited evidence that, when delivered intensively, both the NDP‐3 and ReST may effect improvement in word accuracy in 4‐ to 12‐year‐old children with CAS, measured by the accuracy of production on treated and non‐treated words, speech production consistency and the accuracy of connected speech.",0,0,0,0,0,0,0,0,0,0,0,
295,The study did not assess functional communication.,0,0,0,0,0,0,0,0,0,0,0,
296,"We are unable to say whether either treatment is better than the other, or better than no treatment or treatment as usual.",0,0,0,0,0,0,0,0,0,0,0,
297,"No evidence currently exists to support the effectiveness of other treatments for children aged 4 to 12 years with idiopathic CAS, without other comorbid neurodevelopmental disorders.",0,0,0,0,0,0,0,0,0,0,0,
298,"No formal analyses were conducted to compare NDP‐3 and ReST by the original study authors, hence one treatment cannot be reliably advocated over the other.",0,0,0,0,0,0,0,0,0,0,0,
299,"Further RCTs replicating this study would strengthen the evidence, which we currently rate as low using the GRADE evidence rating system (i.e.",0,0,0,0,0,0,0,0,0,0,0,
300,that 'further research is very likely to have an important impact on our confidence in the estimate and is likely to change the estimate').,0,0,0,0,0,0,0,0,0,0,0,
301,"Further well‐controlled studies investigating the effectiveness of other treatments for CAS are also needed across other motor‐based therapies, and also across linguistic and multi‐modal approaches.",0,0,0,0,0,0,0,0,0,0,0,
302,"As noted earlier in the Why it is important to do this review section, non‐RCT case series or case‐control studies examining motor, linguistic and multi‐modal interventions for CAS have described positive effects of intervention, but RCTs are required to strengthen the evidence base for these approaches.",0,0,0,0,0,0,0,0,0,0,0,
303,"Further, there is also a need for trials that examine interventions for CAS compared to no treatment (e.g.",0,0,0,0,0,0,0,0,0,0,0,
304,"A no‐treatment comparison is arguably difficult to achieve in this field however, given the typically severe presentation of speech disorder and reticence of parents or clinicians (or both) to withhold treatment from children.",0,0,0,0,0,0,0,0,0,0,0,wait‐list control group).
305,"Finally, RCTs are also needed on populations with CAS and co‐occurring neurodevelopmental or medical disorders.",0,0,0,0,0,0,0,0,0,0,0,
306,"Cochrane Reviews are often criticised in the SLP/SLT field because they do not allow consideration of lower levels of evidence, such as case studies or case series, which are more commonly performed in the field.",0,0,0,0,0,0,0,0,0,0,0,
307,"Recognising these concerns we have provided a summary of the observational studies of CAS interventions excluded from this review (see Table 1), to encourage future, rigorous and controlled investigation of the efficacy of these methods.",0,0,0,0,0,0,0,0,0,0,0,
308,The lack of RCT intervention data in the CAS field to date is reinforced by challenges of: (1) the low incidence of the disorder; (2) the lack of a universally applied diagnostic classification system; (3) a lack of understanding of the aetiology of CAS; and (4) the challenge of designing trials for children with co‐occurring clinical features (e.g.,0,0,0,0,0,0,0,0,0,0,0,
309,non‐verbal cognitive impairment) or disorders (e.g.,0,0,0,0,0,0,0,0,0,0,0,
310,"intellectual disability, autism spectrum disorder).",0,0,0,0,0,0,0,0,0,0,0,
311,Overall completeness and applicability of evidence,0,0,0,0,0,0,0,0,0,0,0,
312,"We identified only one small RCT for inclusion in this review, indicating that there is an urgent need for further RCTs in this field.",1,0,0,0,0,0,0,0,0,0,0,
313,The interventions examined are currently in use and therefore results are applicable to clinical practice.,0,0,0,0,0,0,0,0,0,0,0,
314,We considered the overall quality of the evidence to be moderate using the GRADE approach; see summary of findings Table for the main comparison.,0,0,0,0,0,0,0,0,0,0,0,Quality of the evidence
315,"We downgraded the quality of the evidence by one level to moderate, due to imprecision, given that only one RCT was identified.",0,0,0,0,0,0,0,0,0,0,0,
316,Potential biases in the review process,0,0,0,0,0,0,0,0,0,0,0,
317,"We carefully managed potential conflicts of interest, as described below under Contributions of authors and Declarations of interest.",0,0,0,0,0,0,0,0,0,0,0,
318,There is a possible risk of language bias given that we only included studies written in English.,0,0,0,0,0,0,0,0,0,0,0,